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Background:  Changes  in serotype  distribution  have  been  induced  after  pneumococcal  conjugate  vaccines
(PCV)  implementation,  and  non-vaccine  serotypes  are  now  circulating.  Among  these  latter  serotypes,
we  aimed  to distinguish  those  with  high  invasive  disease  potential  before  (2008–2009)  and after  PCV13
implementation  (2012–2013).
Methods:  Invasive  pneumococcal  disease  (IPD)  serotypes  isolated  from  children  6 to  24 months  were
compared  with nasopharyngeal-colonizing  serotypes  in healthy  children.  To  assess  the  invasive  potential
of  a given  serotype,  odds  ratios  (ORs) were  calculated.  For  each  serotype,  OR  >1 indicated  increased
probability  of  association  with  IPD  and  OR <1 decreased  probability.
Results:  In 2008/2009  and  2012/2013,  355  pneumococci  were  isolated  from  1212  healthy  children  and
from  569  IPD,  including  166  meningitis,  114  pneumonia,  and  289  other  IPDs.  In  period  1,  serotypes  7F,  3,
1, 24F,  and 19A  showed  highly  signiﬁcant  invasive  disease  potential  whereas  in period  2, only  serotype
24F  was  associated  with  a  signiﬁcant  high  OR  (6.6  [95%  CI  2.6;  16.2]).  Of note,  for  serotype  12F,  OR  could
not  be  calculated  because  of  no carrier  recorded,  however,  if there  had  been  a single  12F carrier,  the  OR
would  be among  the  highest,  in  period  2, 15.7  [95%  3.4; 73.0]).  Only  two  serotypes  appeared  negatively
associated  with  IPD, 11A  and  23B in  the  period  2 as  compared  with  nine  in  period  1. In  the  second  period,
pneumococcal  penicillin  non-susceptible  isolates  were  mostly  represented  by  serotypes  19A,  15A,  19F,
35B  and  24F both  in  carriers  and  IPD.  Only  one  strain  was  resistant  to penicillin  with  MIC  = 4 g/ml
(serotype  19A)  during  the  ﬁrst period.
Conclusion:  In children  <2 years  old,  compared  to  the  previous  period,  the number  of  serotypes  having  a
high disease  potential  decreased  after  PCV13  implementation,  only  two  non-vaccine  serotypes,  24F and
12F, had  high  invasive  disease  potential.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionNasopharyngeal (NP) ﬂora is the ecological niche of Strepto-
occus pneumoniae (Sp) and the reservoir of strains implicated in
∗ Corresponding author at: ACTIV/CRC/Université Paris Est, IMRB- GRC GEMINI,
4000 Créteil, France. Tel.: +0033 148850404; fax: +0033 148851858.
E-mail address: corinne.levy@activ-france.fr (C. Levy).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.015
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
invasive pneumococcal disease (IPD) and non-invasive infection
[1]. Each pneumococcal infection is preceded by the acquisition
of Sp strains in NP [2,3]. More than 94 serogroups have been rec-
ognized and could be implicated in disease and carriage. However,
before pneumococcal conjugate vaccines implementation (PCVs),
only ﬁve to 11 were responsible for 90% of childhood IPD cases in
developed countries and serotypes reported from carriage stud-
ies were distributed differently from those involved in invasive
pneumococcal disease [4,5].
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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The concept of invasive disease potential in pneumococci infec-
ion was developed from the early 2000s with the implementation
f the seven-valent pneumococcal conjugate vaccine (PCV7) [6]. A
ew studies have compared, for a given serotype, the case carrier
atio to determine the invasiveness of speciﬁc serotypes [6–8]. In
hese studies, conducted in different countries, vaccine serotypes
, 14, and 18C (included in PCV7 and PCV13) and 1, 5 7F, and 19A
included in PCV13) had signiﬁcant odds ratios (ORs) or invasive
ndices for IPD, which suggested their invasive disease potential.
fter the implementation of PCVs, the incidence of IPD markedly
ecreased in all countries where these vaccines were introduced
9–12]. The reduction in IPD incidence is related to the decrease in
accine-type (VT) IPD (from 79% to 100%), but the global efﬁcacy
gainst pneumococcal infections was partially reduced in many
ountries by the increase in non-VT (NVT) IPD [10,13,14].
Most VT PCVs have disappeared from NP ﬂora, and in this
cological niche, the almost complete replacement by NVTs is
ccompanied by minimal changes in overall pneumococcal carriage
15–17]. One of the main hypotheses to explain the discrepancy
etween carriage and disease is the lesser disease potential of most
f the NVTs carried after PCV implementation. However, little is
nown about the invasive disease potential of NVTs, so we  need
o elucidate which serotypes are prone to give more frequently
nvasive diseases [10,18,19].
In France, since 2008, PCV7 coverage (immunization schedule
 + 1) for children <2 years old has been high (≥86%) [20]. In June
010, the French authorities recommended routine vaccination
ith PCV13 for infants at 2, 4 and 12 months old to replace PCV7,
ithout catch-up for older children except those at high risk of
PD [21]. The PCV vaccination coverage in France for children <2
ears old after replacement of PCV7 with PCV13 was >92% [20].
n parallel, taking advantage of our ongoing surveys concerning
oth IPD and pneumococcal carriage before and after PCV13 imple-
entation, we aimed to estimate the invasive disease potential of
erotypes, with a special attention to emerging serotypes, in the
CV13 era.
. Patients and methods
The serotype speciﬁc relationship between NP carriage and IPD
as investigated by comparing the serotype speciﬁc prevalence in
arriage and in invasive isolates in two periods, before and after
CV13 implementation.
.1. Population
.1.1. Carriage study
Between January 2008 and December 2013, 90 pediatricians
hroughout France took part in this prospective study. Each year,
00 healthy children of both sexes, aged 6 to 24 months, consul-
ing for well-baby visits (generally for routine immunization) and
ithout fever or respiratory symptoms were enrolled. We excluded
hildren receiving antibiotic treatment within 7 days before enrol-
ent, with severe underlying disease. In addition, we  excluded
hildren already enrolled during the last 12 months.
After written informed consent was obtained from parents, we
ueried parents or guardians regarding the child’s medical record
o document the status of PCV vaccination. The study was  approved
y the Saint Germain en Laye Hospital Ethics Committee. NP spec-
mens were obtained by using cotton-tipped wire swabs. The
wabs were inserted into the nares, gently rubbed on the NP wall,
emoved, and immediately placed in transport medium (Copan
enturi Transystem®, Brescia, Italy). The samples were transferred
ithin 48 h to central laboratories (French National Reference Cen-
re for Pneumococci [NRCP] and Robert Debré Hospital). (2015) 6178–6185 6179
2.1.2. IPD study
Pneumococcal invasive cases were deﬁned by the isolation of
pneumococcus from a normally sterile site (cerebrospinal ﬂuid
or blood or pleural ﬂuid). IPD surveillance relies on data gener-
ated by the NRCP. Invasive strains were collected as part of the
French national survey program of pneumococcal infections, via
the “Observatoires Régionaux du Pneumocoque”, a network of 400
laboratories located in the 22 regions of France and covering at
least 70% of the admissions in medical wards [22]. Data collected
included age, sex, site of isolation, and the disease.
Analysis was  performed on data for patients 6 to 24 months old
that was  extracted from this database during the carriage study
(January 2008 to December 2013).
For both studies,  S. pneumoniae was  identiﬁed by standard
methods and serotyped at the NRCP by latex agglutination test-
ing with antisera provided by Statens Serum Institut (Copenhagen,
Denmark) [23]. Serotypes 15B and 15C were considered the single
serotype 15B/C because the capsule is quickly interchangeable [24].
Susceptibility of S. pneumoniae isolates to penicillin G was
determined by minimal inhibitory concentration (MIC) by the agar-
dilution method. Isolates were classiﬁed as penicillin-susceptible
(PSP; MIC  ≤ 0.06 g/ml), penicillin–non-susceptible (PNSP;
MIC  ≥ 0.12 g/ml), or penicillin-resistant (PRP; MIC  > 2 g/ml)
according to the European Committee on antimicrobial suscepti-
bility testing. (http://www.eucast.org/clinical breakpoints/)
2.2. Statistical analysis
Two  periods were deﬁned according to PCV13 implementa-
tion in France: the ﬁrst, before the PCV13 era (January 2008 to
December 2009) and the second, the PCV13 era (January 2012
to December 2013). Data for years 2010 and 2011, corresponding
to PCV13 implementation in France, were excluded from the anal-
ysis. Four groups were deﬁned: healthy carriers and those with
meningitis, pneumonia or other IPDs. The ﬁrst analysis compared
healthy carriers to the whole IPD group, including those with
meningitis, pneumonia and other IPDs. The second one applied to
healthy carriers versus meningitis versus pneumonia versus other
IPDs.
Quantitative data were analyzed by one-way ANOVA and cat-
egorical data by chi-square test or Fisher’s exact test. Statistical
signiﬁcance was  set at two-sided p < 0.05. Stata SE 12.1 (Statacorp,
College Station, TX) was  used for analysis.
To estimate the invasive disease potential of serotypes, we com-
pared the serotype-speciﬁc rates of isolation with carriage and
invasive diseases. To assess the invasive disease potential of a given
serotype, odds ratios (ORs) were calculated by reference to the
other serotypes. For each serotype, OR > 1 indicated an increased
probability to cause IPD and OR < 1 decreased probability.
3. Results
3.1. Epidemiology
During the two periods studied (2008/2009 and 2012/2013),
among 1212 healthy children, 355 pneumococci strains were iso-
lated and 569 IPD were recorded: 166 meningitis, 114 pneumonia,
and 289 other IPDs. For this pooled dataset (n = 924), mean ± SD age
was 13.4 ± 5.3 months (median 12.3). Table 1 shows the distribu-
tion of cases by type of IPD, period and age.
For healthy controls, among the 32 serotypes found in period
1, the most common were 19A (14.5%), 15B/C (11.9%), 15A (6.7%),
and 6C (6.7%). In period 2, among the 30 serotypes found, the main
ones were 15B/C (13.6%), 23B (9.3%), 15A (8.6%), 11A (8.0%), and
10A (6.8%) (Fig. 1). For IPD, among the 40 serotypes found in period
6180 E. Varon et al. / Vaccine 33 (2015) 6178–6185
Table  1
Population by pathology, period and age.
Overall, n = 924 Carriers n = 355 IPD (total) n = 569 Meningitis n = 166 Pneumonia n = 114 Other IPDs n = 289 p* p**
Period 1 (2008/2009), n = 581 193 (33.2)  388 (66.8) 102 (17.6)  85 (14.6) 201 (34.6)
Age  (months), mean ± SD (median) 13.2 ± 5.4 (12.3) 13.4 ± 5.2 (12.2) 11.7 ± 5.2 (10.0) 13.7 ± 4.9 (13.7) 14.1 ± 5.1 (13.4) 0.7 0.002
Period  2 (2012/2013), n = 343 162 (47.2)  181 (52.8) 64 (18.7) 29 (8.5) 88 (25.7)
Age  (months), mean ± SD (median) 13.9 ± 5.5 (12.9) 13.1 ± 5.0 (12.3) 11.6 ± 4.7 (10.5) 14.7 ± 5.3 (14.2) 13.7 ± 4.9 (13.6) 0.18 0.012
Data are no. (%) unless indicated. IPD, invasive pneumococcal disease. Other IPD: bacteremia without source, osteo articular infection, pericarditis, peritonitis, cellulitis.
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[* Student’s t test p-value for age comparing carriers vs IPD total cases.
** ANOVA p-value for age comparing carriers vs meningitis vs pneumonia and vs 
, three, 19A, 7F, and 1 were implicated in 54.4% of cases; among the
1 serotypes isolated in period 2, the three leading serotypes (24F,
9A, and 12F) accounted for 37.6% of cases (p < 0.001 between the
wo periods). Of note, serotypes 1 and 7F in period 1 and serotype
2F in period 2 were quasi-exclusively found among IPD isolates
nd not in carriers (Fig. 1). In the ﬁrst period, PNSP isolates were
ostly represented by serotypes 19A, 15A, 15B/C, NT, 19F and 35B
n carriers and 19A, 24F, 19F, 15A and 14 in IPD cases. Only one
train was resistant to penicillin with MIC  = 4 g/ml (serotype 19A)
uring the ﬁrst period. In the second period, PNSP isolates were
ostly represented by serotypes 19A, 15A, 19F, 35B and 24F both
n carriers and IPD.
Table 2 presents the distribution of main serotypes by type of
PD and period (Supplemental Table 2 presents overall serotypes).
ompared to period 1, during period 2, the number of pneumo-
occal isolates was reduced for overall IPD (53.4%), meningitis
37.2%), pneumonia (65.9%), and other IPDs (56.2%). PCV7 serotypes
lmost disappeared between the 2 periods, regardless of pathol-
gy, except for serotype 19F, accounting for 3.9% of IPD isolates.
he frequency of the six additional PCV13 serotypes signiﬁcantly
ecreased between the 2 periods for overall IPD, meningitis, pneu-
onia, and other IPDs, from 60.8% to 12.2%, 48.2% to 11.0%, 67.0%
o 17.2%, and 64.7% to 11.4%, respectively (p < 0.001 for each com-
arison). In overall IPD, the frequency of serotype 19A decreased
etween the 2 periods from 33% to 8.8% and ranked second in period
 after the serotype 24F which accounted for 19.9% of cases.
.2. Invasive disease potential
Serotype-speciﬁc ORs were compared in each period (Fig. 2). Of
he 40 serotypes found in IPD in period 1, ﬁve showed highly sig-
iﬁcant invasive disease potential: 7F, 3, 1, 24F, and 19A. In period
, only serotype 24F was associated with a signiﬁcant high OR (6.6
95% CI 2.6; 16.2]). Of note, for ST 12F, considered a highly invasive
erotype [8,25], ORs could not be calculated because of no carrier
ecorded in both periods. However, if there had been a single 12F
arrier during each study period, 12F ORs would be among the high-
st, although signiﬁcant only in the second period (OR period 1,
.6 [95% 0.7; 30.3], and period 2, 15.7 [95% 3.4;73.0]). Among the
erotypes isolated in the period 1, nine were negatively associated
ith IPD, 15B/C, 15A, 35F, 21, 23A, 23B, 35B, 6A and 6C. In period
, two serotypes appeared negatively associated with IPD, 11A and
3B.
. Discussion
The design of this study allowed us to analyze a large national
ollection of isolates from invasive disease and carriage in children
 to 24 months old to compare the invasive disease potential of
redominant serotypes before and after PCV13 implementation. To
stimate the serotype-speciﬁc invasive disease potential we used
nvasive ORs rather than invasive capacity or attack rate because
nvasive ORs have been used most frequently in the literature
7,8,26–28].IPD.
Before PCV7 implementation, serotypes 1, 4, 5, 14, 18C, and 12F
were the most invasive serotypes [6,8]. After the widespread imple-
mentation of PCV7, serotypes 3, 7F, 18C, 19A, 22F and 33F were
highly invasive [29]. To our knowledge, our large study is the ﬁrst
to analyze serotype pneumococci invasiveness before and after the
PCV13 era. The number of serotypes with high invasive disease
potential decreased from ﬁve (7F, 3, 1, 24F, and 19A) to one (24F)
between the PCV7 and PCV13 periods. Of note, the serotypes 7F, 3,
and 1, with very high invasiveness in the PCV7 period, disappeared
in 2012–2013. Serotype 24F had the highest invasive disease poten-
tial (OR 6.5 [95% 2.6; 16.2]) during the PCV13 period. In light of our
results, only this serotype maintained the same invasiveness before
and after PCV13 implementation. For serotype 12F, the second pre-
dominant serotype in IPD in the PCV13 era, although no carrier was
recorded, a strong invasive disease potential was expected. This
expectation was conﬁrmed because by estimating a single carrier,
the OR was  the highest (OR 15.7 [95% 3.4; 73.0]). Of  note, such a
high OR was found only for serotype 7F (OR 15.1 [95% 11.6; 49.6])
during the PCV7 period. This result was expected because both 12F
and 7F were reported to be hyperinvasive as compared with other
IPD strains and found more often in meningitis [8,11,25,30–32].
These results were observed in the context of a decrease in
IPD in several countries [9–11,18,19,33]. A marked decrease in IPD
cases after PCV13 implementation in children <2 years old was  also
reported by different surveillance networks in France. Indeed, IPD
and meningitis incidence signiﬁcantly decreased by 30% and 20%,
respectively, between 2008/2009 and 2012 (24.6 to 17.2/100 000
and 5.6 to 4.5/100 000) [10]. For children <2 years old, even if PCV13
coverage was >92%, PCV13 serotypes were not yet totally elimi-
nated from IPD because they still accounted for 12.2% of cases in
period 2. This ﬁnding is not surprising because few cases probably
occurred in non-vaccinated children. Moreover the immunization
schedule (2 + 1) used in France as compared with the US one (3 + 1)
could have contributed to this absence of total disappearance. The
last explanation could be the effectiveness of the vaccine measured
only after 3 years of implementation.
In the PCV13 period, a relatively small number of pneumococ-
cal serotypes were responsible for most cases of IPD in children
6 to 24 months old. Indeed, six serotypes, 24F, 19A, 12F, 15B/C,
10A, and 15A, represented 60.7% of IPD cases. PNSP isolates were
mostly represented by the serotypes 24F, 19A, and 15A. Serotype
24F ranked ﬁrst, both for meningitis and pneumonia, and serotypes
12F and 19A were the second predominant serotype in meningi-
tis and pneumonia, respectively. Among the other most prevalent
non-PCV13 serotypes (15B/C, 10A, and 15A, sorted by frequency)
serotype 10A was  invasive (OR > 1), whereas serotypes 15B/C and
15A appeared negatively associated with IPD (OR < 1), but not sig-
niﬁcantly. Browall et al. reported a lower invasive disease potential
for NVT before PCV13 implementation, as did van Hoek et al. for the
PCV13 era [34,35]. Interestingly, in our study, serotypes 11A and
23B showed low invasive disease potential [7,25,27,34,36].
For most of the other NVT, the risk of IPD cannot be assessed
in our study because of the low number of IPD cases (22F and
33F). By contrast, serotypes 22F and 33F increased in frequency and
E. Varon et al. / Vaccine 33 (2015) 6178–6185 6181
Fig. 1. Streptococcus pneumoniae serotype distribution by resistance proﬁle in healthy carriers and in invasive diseases before (2008/2009) and after (2012/2013) 13 valent
pneumococcal conjugate vaccine implementation. * Only one strain with penicillin MIC  = 4 g/ml (serotype 19A).
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Table  2
Distribution of main serotypes by type of IPD and period.
* to per
w
E
t
a
i
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q Evolution of the rank (based on serotype prevalence) from period 1 (2008–2009) 
ere among the most frequent serotypes in IPD in North America,
ngland and Wales [37–39]. We  could not assess the risk of IPD due
o the similar frequency of serotypes 15B/C and 15A both in carriage
nd IPD. However, in children <2 years old, who have immature
mmunity, these carriage serotypes are known to be associated
ith IPD [23]. Because we enrolled only children <2 years, fre-
uently pneumococcal carriers, our results cannot be completelyiod 2 (2012–2013).
extrapolated to older children and this is the ﬁrst limitation of our
study.
Some other limitations should be taken into account when inter-
preting our results. The estimated serotype invasiveness could be
biased by variation in duration of carriage [3,25]. Sleeman et al.
reported an inverse relationship between the attack rate of a cap-
sular serotype and duration of carriage. Serotypes with a short
E. Varon et al. / Vaccine 33 (2015) 6178–6185 6183
F ison to
( al bar
d
w
s
t
h
hig. 2. Serotype-speciﬁc odds ratios (and 95% CIs) for invasive disease by compar
2012/2013) 13 valent pneumococcal conjugate vaccine implementation. The vertic
uration of carriage were signiﬁcantly more likely to be those
ith high attack rates [25]. This ﬁnding was well illustrated by
erotype 12F (with probably the strongest invasive disease poten-
ial) reported to have one of the shortest carriage duration [25].
The third limitation is related to our distribution of IPD: we may
ave overestimated meningitis cases, and pneumonia cases may
ave been underrepresented. In period 2, meningitis represented healthy carriers, by period of PCV implementation before (2008/2009) and after
s separate signiﬁcant from non-signiﬁcant serotype-speciﬁc odds ratios.
35.5% of cases and pneumonia 16% of cases. This IPD distribu-
tion is not the one usually observed in France because the French
Institute for Public Health Surveillance reported that meningitis
accounted for 26% of IPD cases in children <2 years old in 2012
[10]. Such discrepancies were reported, in the Kaplan et al. study,
where meningitis and pneumonia accounted for 18.5% and 25% of
cases, whereas in the Ben-Shimol et al. study, these rates were
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.4% and 35.5%, respectively [19,40]. Such differences in diagnosis
istribution could be explained by the method of collecting data,
se of electronic data capture, mandatory declaration of cases, and
rganization of public health programs for pneumococcal surveil-
ance. Likewise, these differences could be due to blood culture
ractices for febrile children or indications for lumbar puncture
12,41]. Another explanation could be the difﬁculty in matching
acteremia with the source of infection, particularly for pneumonia
n children. However, from our results, a more thorough meningitis
ase-reporting cannot be ruled out. However, if these difﬁculties in
ata collection represent a limitation of our study, we emphasize
hat our methodology did not change in the two periods.
The last limitation is the absence of analysis by multilocus
equence typing (MLST). Indeed, the invasive disease potential of
neumococci seems to be determined by capsular serotype rather
han genotype, as determined by MLST [26]. However, the diver-
ity in genotype contributes to the heterogeneity of invasive disease
otential in a given serotype [7,36].
. Conclusion
The number of serotypes with high invasive disease poten-
ial decreased after PCV13 implementation, only two non-vaccine
erotypes, 24F and 12F, had high invasive disease potential in chil-
ren <2 years old. By contrast, serotypes 11A and 23B appeared
egatively associated with IPD. This study is valuable to improve
ur knowledge of the emerging serotypes, especially their invasive
isease potential. Furthermore, such studies seem to be pertinent
or accurately choosing the serotypes to add to the formulation of
uture vaccines. This study points out some changes occurring only
hree years after PCV13 implementation and suggests that a new
quilibrium in the pneumococcal population is not yet reached.
owever, this reﬂects the epidemiology of pneumococci in France,
nd we are aware that post-PCV13 emerging serotypes could be
ifferent in other countries. Therefore, ongoing surveys performed
oncomitantly for carriage and IPD are needed to further charac-
erize the little-known NVT, which are still poorly represented.
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